Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31186659 | 1.00 | L3MBTL1 (0.41) | L3MBTL1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL28288419 | 0.85 | MAPT (0.52) | L3MBTL1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL6795825 | 0.83 | KDM4E (0.54) | L3MBTL1MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL29755815 | 0.83 | KDM4E (0.54) | L3MBTL1MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL17842217 | 0.81 | RXRA (0.46) | L3MBTL1MEN1KMT2AHSD17B10CYP1A2 | |
| SCHEMBL17848349 | 0.81 | RXRA (0.46) | L3MBTL1MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL10030736 | 0.81 | L3MBTL1 (0.46) | L3MBTL1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL21385775 | 0.81 | L3MBTL1 (0.41) | L3MBTL1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL2350644 | 0.81 | AR (0.47) | L3MBTL1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL3341627 | 0.81 | KDM4E (0.67) | L3MBTL1MAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108033906-B | Preparation method of silodosin intermediate | 常州瑞明药业有限公司 | 2021-07-06 | — | — | CN | claimed |
| EP-3892615-A1 | PROCESS FOR THE PREPARATION OF SILODOSIN | Minakem (FR) | 2021-10-13 | — | — | EP | disclosed |
| CN-108033906-B | Preparation method of silodosin intermediate | 常州瑞明药业有限公司 | 2021-07-06 | — | — | CN | disclosed |
| US-9745264-B2 | Method for preparing silodosin and intermediate thereof | SHANGHAI SYNCORES TECHNOLOGIES, INC. (CN) | 2017-08-29 | — | — | US | disclosed |
| US-9745264-B2 | Method for preparing silodosin and intermediate thereof | SHANGHAI SYNCORES TECHNOLOGIES, INC. (CN) | 2017-08-29 | — | — | US | disclosed |
| US-20160304452-A1 | METHOD FOR PREPARING SILODOSIN AND INTERMEDIATE THEREOF | ZHEJIANG HUAHAI PHARMACEUTICALS CO., LTD. (CN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304452-A1 | METHOD FOR PREPARING SILODOSIN AND INTERMEDIATE THEREOF | ZHEJIANG HUAHAI PHARMACEUTICALS CO., LTD. (CN) | 2016-10-20 | — | — | US | disclosed |
| EP-2125717-B1 | DEUTERATED DERIVATIVES OF SILODOSIN AS ALPHA IA-ADRENORECEPTOR ANTAGONISTS | CONCERT PHARMACEUTICALS INC (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012062229-A1 | A METHOD OF MANUFACTURING (-)-L-(3-HYDROXYPROPYL)-5-[(2R)-2-({2,2,2-TRIFLUOROETHOXY)- PHENOXYETHYL}AMINO)PROPYL]-2,3-DIHYDRO-LH-INDOLE-7-CARBOXAMIDE | ZENTIVA, K.S. (CZ) | 2012-05-18 | — | — | WO | disclosed |
| US-8013007-B2 | Alpha 1A-adrenoceptor antagonists | CONCERT PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100076010-A1 | ALPHA 1A-ADRENOCEPTOR ANTAGONISTS | CONCERT PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20100069668-A1 | 5-[(2R)-[2-[2-(2,2,2-TRIFLUOROETHOXY)PHENOXY]ETHYL]AMINO]PROPYL]-2-METHOXYBENZENESULFONAMIDE | JIANGSU HANSEN PHARMACEUTICAL CO., LTD. (CN) | 2010-03-18 | — | — | US | disclosed |
| US-20100069668-A1 | 5-[(2R)-[2-[2-(2,2,2-TRIFLUOROETHOXY)PHENOXY]ETHYL]AMINO]PROPYL]-2-METHOXYBENZENESULFONAMIDE | JIANGSU HANSEN PHARMACEUTICAL CO., LTD. (CN) | 2010-03-18 | — | — | US | disclosed |
| EP-2125717-A2 | DEUTERATED DERIVATIVES OF SILODOSIN AS ALPHA IA-ADRENORECEPTOR ANTAGONISTS | Concert Pharmaceuticals Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2098503-A1 | 5-[(2R)-[2-[2-[2-(2,2,2-TRIFLUOROETHOXY)PHENOXY]ETHYL]AMINO]PROPYL]-2-METHOXYBENZENESULFONAMIDE | Jiangsu Hansen Pharmaceutical Co., Ltd. (CN) | 2009-09-09 | — | — | EP | disclosed |
| US-20090012112-A1 | Alpha 1A-adrenoceptor antagonists | CONCERT PHARMACEUTICALS, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008106125-A2 | DEUTERATED DERIVATIVES OF SILODOSIN AS ALPHA LA-ADRENOCEPTOR ANTAGONISTS | CONCERT PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| EP-0600675-B1 | Indoline compounds for the treatment of dysuria | KISSEI PHARMACEUTICAL (JP) | 1998-07-08 | — | — | EP | disclosed |
| US-5387603-A | Treating dysuria (painful urination) with less hypotension; FDA Orange book listed patent for silodosin | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1995-02-07 | — | — | US | disclosed |
| EP-0600675-A1 | Indoline compounds for the treatment of dysuria | Kissei Pharmaceutical Co., Ltd. (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076010-A1 | ALPHA 1A-ADRENOCEPTOR ANTAGONISTS | ADRA1D, ADRA1A, ADRB1 | L3MBTL1 3416/4885MAPT 2031/4885KDM4E 3568/4885 |
| US-20090012112-A1 | Alpha 1A-adrenoceptor antagonists | ADRA1D, ADRA1A, ADRB1 | L3MBTL1 3416/4885MAPT 2031/4885KDM4E 3568/4885 |
| US-20100069668-A1 | 5-[(2R)-[2-[2-(2,2,2-TRIFLUOROETHOXY)PHENOXY]ETHYL]AMINO]PROPYL]-2-METHOXYBENZENESULFONAMIDE | ADRB2, ADRB1, ADRA2B | L3MBTL1 4853/4885MAPT 1645/4885KDM4E 1828/4885 |
| US-20160304452-A1 | METHOD FOR PREPARING SILODOSIN AND INTERMEDIATE THEREOF | PTMA, PIR, ERG28 | L3MBTL1 3673/4885MAPT 4036/4885KDM4E 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.